Best of ASCO 2021—bladder cancer
- 25.10.2021
- ASCO 2021
- short review
Erschienen in:
- Verfasst von
- Karl Mayrhofer, MD
- Dora Niedersüß-Beke, MD, MBA
- Erschienen in
- memo - Magazine of European Medical Oncology | Ausgabe 4/2021
Summary
Three trials presented at the meeting investigated the incorporation of immunotherapy into a multimodal bladder-sparing treatment approach. The results of these phase 2 trials are so far promising with most patients achieving complete remission (CR) and estimated bladder-intact disease-free survival (BIDFS) in these patients ranges between 73 and 88%. Additionally, the up to 5-year follow-up data from the KEYNOTE-052 study were discussed. The results confirm the efficacy of pembrolizumab as first-line monotherapy in cisplatin-ineligible patients with a programmed death ligand 1 (PD-L1) combined positive score (CPS) ≥ 10.
Anzeige
- Titel
- Best of ASCO 2021—bladder cancer
- Verfasst von
-
Karl Mayrhofer, MD
Dora Niedersüß-Beke, MD, MBA
- Publikationsdatum
- 25.10.2021
- Verlag
- Springer Vienna
- Schlagwort
- ASCO 2021
- Erschienen in
-
memo - Magazine of European Medical Oncology / Ausgabe 4/2021
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076 - DOI
- https://doi.org/10.1007/s12254-021-00765-7
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.